Novo Nordisk localizes production in the Kaluga Region

09 July 2021

Novo Nordisk is at the first phase of localization of new generation insulin at its facility in the Kaluga Region.

45.7 mln
Jobs: 155
Kaluga region

Investor profile

Novo Nordisk A/S


Company's website:

T: +45 4444 8888

Public company (NVO)


Contact: Lars Rebien Sørensen, CEO

The world’s biggest insulin maker.